Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
Ajay K Nooka, Katja Weisel, Niels Wcj van de Donk, David Routledge, Paula Rodriguez Otero, Kevin Song, Hang Quach, Natalie Callander, Monique C Minnema, Suzanne Trudel, Nicola A Jackson, Christoph M Ahlers, Ellie Im, Shinta Cheng, L Smith, Nahi Hareth, Geraldine Ferron-Brady, Maria Brouch, Rocio Montes de Oca, Sofia Paul, Beata Holkova, Ira Gupta, Brandon E Kremer, Paul Richardson, Ajay K Nooka, Katja Weisel, Niels Wcj van de Donk, David Routledge, Paula Rodriguez Otero, Kevin Song, Hang Quach, Natalie Callander, Monique C Minnema, Suzanne Trudel, Nicola A Jackson, Christoph M Ahlers, Ellie Im, Shinta Cheng, L Smith, Nahi Hareth, Geraldine Ferron-Brady, Maria Brouch, Rocio Montes de Oca, Sofia Paul, Beata Holkova, Ira Gupta, Brandon E Kremer, Paul Richardson
Abstract
Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma. Clinical trial registration: NCT04126200 (ClinicalTrials.gov).
Keywords: BCMA; GSK3174998; antibody–drug conjugate; belantamab mafodotin; clinical trial; dostarlimab; feladilimab; multiple myeloma; nirogacestat; platform study.
Source: PubMed